{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:27:54Z","timestamp":1789194474600,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The State Administration of Science Technology and Industry for National Defense","award":["HNKFHBZ202322"],"award-info":[{"award-number":["HNKFHBZ202322"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["12475349"],"award-info":[{"award-number":["12475349"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2023NSFSC1714"],"award-info":[{"award-number":["2023NSFSC1714"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA184228"],"award-info":[{"award-number":["CA184228"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00259-025-07754-6","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:25:58Z","timestamp":1770708358000},"page":"4446-4459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["First-in-human evaluation of [211At]YF2 in patients with metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3518-9689","authenticated-orcid":false,"given":"Xiaoai","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhao","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Zalutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9255-3048","authenticated-orcid":false,"given":"Feize","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5191-9004","authenticated-orcid":false,"given":"Rong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"7754_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"7754_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231157632","volume":"15","author":"A Jang","year":"2023","unstructured":"Jang A, Kendi AT, Sartor O. Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials. Ther Adv Med Oncol. 2023;15:17588359231157632. https:\/\/doi.org\/10.1177\/17588359231157632.","journal-title":"Ther Adv Med Oncol"},{"key":"7754_CR3","doi-asserted-by":"publisher","first-page":"914","DOI":"10.2967\/jnumed.114.147413","volume":"56","author":"M Bene\u0161ov\u00e1","year":"2015","unstructured":"Bene\u0161ov\u00e1 M, Sch\u00e4fer M, Bauder-W\u00fcst U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914\u201320. https:\/\/doi.org\/10.2967\/jnumed.114.147413.","journal-title":"J Nucl Med"},{"key":"7754_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"7754_CR5","first-page":"174","volume":"32","author":"WA Volkert","year":"1991","unstructured":"Volkert WA, Goeckeler WF, Ehrhardt GJ, Ketring AR. Therapeutic radionuclides: production and decay property considerations. J Nuclear Medicine: Official Publication Soc Nuclear Med. 1991;32:174\u201385.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"key":"7754_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2015.00012","volume":"2","author":"JP Pouget","year":"2015","unstructured":"Pouget JP, Lozza C, Deshayes E, Boudousq V, Navarro-Teulon I. Introduction to radiobiology of targeted radionuclide therapy. Front Med. 2015;2:12. https:\/\/doi.org\/10.3389\/fmed.2015.00012.","journal-title":"Front Med"},{"key":"7754_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00996","volume":"9","author":"BM Bavelaar","year":"2018","unstructured":"Bavelaar BM, Lee BQ, Gill MR, Falzone N, Vallis KA. Subcellular targeting of theranostic radionuclides. Front Pharmacol. 2018;9:996. https:\/\/doi.org\/10.3389\/fphar.2018.00996.","journal-title":"Front Pharmacol"},{"key":"7754_CR8","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2967\/jnumed.120.251017","volume":"62","author":"MJ Zacherl","year":"2021","unstructured":"Zacherl MJ, Gildehaus FJ, Mittlmeier L, B\u00f6ning G, Gosewisch A, Wenter V, et al. First clinical results for PSMA-Targeted \u03b1-Therapy using (225)Ac-PSMA-I&T in Advanced-mCRPC Patients. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2021;62:669\u201374. https:\/\/doi.org\/10.2967\/jnumed.120.251017.","journal-title":"Soc Nuclear Med"},{"key":"7754_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2024.108916","volume":"134","author":"Y Feng","year":"2024","unstructured":"Feng Y, Meshaw RL, Finch SW, Zheng Y, Minn I, Vaidyanathan G, et al. A third generation PSMA-targeted agent [(211)At]YF2: synthesis and in vivo evaluation. Nucl Med Biol. 2024;134:108916. https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108916.","journal-title":"Nucl Med Biol"},{"key":"7754_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07578-4","author":"Y Feng","year":"2025","unstructured":"Feng Y, Huynh TT, Zheng Y, Banks RL, Pomper MG, Vaidyanathan G, et al. Effective treatment of human prostate carcinoma xenografts with Single-Dose PSMA-targeted [(211)At]YF2. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07578-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7754_CR11","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00259-020-05057-6","volume":"48","author":"EAM Ruigrok","year":"2021","unstructured":"Ruigrok EAM, van Vliet N, Dalm SU, de Blois E, van Gent DC, Haeck J, et al. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging. 2021;48:1339\u201350. https:\/\/doi.org\/10.1007\/s00259-020-05057-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7754_CR12","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/mnm.0000000000001658","volume":"44","author":"MJM Uijen","year":"2023","unstructured":"Uijen MJM, Priv\u00e9 BM, van Herpen CML, Westdorp H, van Gemert WA, de Bakker M, et al. Kidney absorbed radiation doses for [ 177 Lu]Lu-PSMA-617 and [ 177 Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry. Nucl Med Commun. 2023;44:270\u20135. https:\/\/doi.org\/10.1097\/mnm.0000000000001658.","journal-title":"Nucl Med Commun"},{"key":"7754_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2967\/jnumed.107.046938","volume":"49","author":"MR Zalutsky","year":"2008","unstructured":"Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, et al. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2008;49:30\u20138. https:\/\/doi.org\/10.2967\/jnumed.107.046938.","journal-title":"Soc Nuclear Med"},{"key":"7754_CR14","doi-asserted-by":"publisher","first-page":"23s","DOI":"10.2967\/jnumed.121.262751","volume":"62","author":"RL Wahl","year":"2021","unstructured":"Wahl RL, Sgouros G, Iravani A, Jacene H, Pryma D, Saboury B, et al. Normal-tissue tolerance to radiopharmaceutical therapies, the knowns and the unknowns. J Nucl Med. 2021;62:23s\u201335s. https:\/\/doi.org\/10.2967\/jnumed.121.262751.","journal-title":"J Nucl Med"},{"key":"7754_CR15","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00259-022-06016-z","volume":"50","author":"T Watabe","year":"2023","unstructured":"Watabe T, Kaneda-Nakashima K, Shirakami Y, Kadonaga Y, Ooe K, Wang Y, et al. Targeted \u03b1-therapy using astatine ((211)At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound. Eur J Nucl Med Mol Imaging. 2023;50:849\u201358. https:\/\/doi.org\/10.1007\/s00259-022-06016-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7754_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2967\/jnumed.108.058651","volume":"51","author":"G Sgouros","year":"2010","unstructured":"Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD pamphlet 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2010;51:311\u201328. https:\/\/doi.org\/10.2967\/jnumed.108.058651.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"key":"7754_CR17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2967\/jnumed.123.267043","volume":"65","author":"M El Fakiri","year":"2024","unstructured":"El Fakiri M, Ayada N, M\u00fcller M, Hvass L, Gamzov TH, Clausen AS, et al. Development and preclinical evaluation of [(211)At]PSAt-3-Ga: an inhibitor for targeted \u03b1-therapy of prostate cancer. J Nucl Med. 2024;65:593\u20139. https:\/\/doi.org\/10.2967\/jnumed.123.267043.","journal-title":"J Nucl Med"},{"key":"7754_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-07017-w","author":"T Watabe","year":"2024","unstructured":"Watabe T, Hatano K, Naka S, Sasaki H, Kamiya T, Shirakami Y, et al. First-in-human SPECT\/CT imaging of [(211)At]PSMA-5: targeted alpha therapy in a patient with refractory prostate cancer. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-07017-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7754_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115667","author":"T Watabe","year":"2024","unstructured":"Watabe T, Kaneda-Nakashima K, Kadonaga Y, Ooe K, Sampunta T, Hirose N, et al. Preclinical evaluation of biodistribution and toxicity of [(211)At]PSMA-5 in mice and primates for the targeted alpha therapy against prostate cancer. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25115667.","journal-title":"Int J Mol Sci"},{"key":"7754_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1210\/jcem-44-2-379","volume":"44","author":"W Jubiz","year":"1977","unstructured":"Jubiz W, Carlile S, Lagerquist LD. Serum thyrotropin and thyroid hormone levels in humans receiving chronic potassium iodide. J Clin Endocrinol Metab. 1977;44:379\u201382. https:\/\/doi.org\/10.1210\/jcem-44-2-379.","journal-title":"J Clin Endocrinol Metab"},{"key":"7754_CR21","doi-asserted-by":"publisher","unstructured":"Fujikawa M, Okamura K. Graves\u2019 hyperthyroidism treated with potassium iodide: early response and after 2 years of follow-up. Eur Thyroid J. 2024;13. https:\/\/doi.org\/10.1530\/etj-24-0085.","DOI":"10.1530\/etj-24-0085"},{"key":"7754_CR22","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.2967\/jnumed.124.267452","volume":"65","author":"Z Ells","year":"2024","unstructured":"Ells Z, Grogan TR, Czernin J, Dahlbom M, Calais J. Dosimetry of [(177)Lu]Lu-PSMA-targeted radiopharmaceutical therapies in patients with prostate cancer: a comparative systematic review and metaanalysis. J Nucl Med. 2024;65:1264\u201371. https:\/\/doi.org\/10.2967\/jnumed.124.267452.","journal-title":"J Nucl Med"},{"key":"7754_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2025.109028","volume":"146","author":"TT Huynh","year":"2025","unstructured":"Huynh TT, Feng Y, Banks RL, Vaidyanathan G, Zalutsky MR. Enhancing the therapeutic index of [(211)At]YF2 with iodo pseudo carrier: a simple strategy for reducing accumulation in kidneys, salivary and lacrimal glands. Nucl Med Biol. 2025;146:109028. https:\/\/doi.org\/10.1016\/j.nucmedbio.2025.109028.","journal-title":"Nucl Med Biol"},{"key":"7754_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1053\/j.semnuclmed.2021.11.003","volume":"52","author":"P Jackson","year":"2022","unstructured":"Jackson P, Hofman M, McIntosh L, Buteau JP, Ravi Kumar A. Radiation dosimetry in (177)Lu-PSMA-617 therapy. Semin Nucl Med. 2022;52:243\u201354. https:\/\/doi.org\/10.1053\/j.semnuclmed.2021.11.003.","journal-title":"Semin Nucl Med"},{"key":"7754_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092592","author":"C Burgard","year":"2023","unstructured":"Burgard C, Rosar F, Marlowe RJ, Bartholom\u00e4 M, Dewes S, Schaefer-Schuler A, et al. Tumor sink effect with prostate-specific membrane antigen-targeted theranostics in patients with metastatic castration-resistant prostate cancer: intra-individual evaluations. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15092592.","journal-title":"Cancers (Basel)"},{"key":"7754_CR26","unstructured":"Oncology therapeutic radiopharmaceuticals: dosage optimization during clinical development. Guidance for Industry. US Food and Drug Administration. August, 2025. https:\/\/www.regulations.gov\/docket\/FDA-2025-D-1757\/document"},{"key":"7754_CR27","doi-asserted-by":"publisher","first-page":"732","DOI":"10.2967\/jnumed.124.269299","volume":"66","author":"K Berner","year":"2025","unstructured":"Berner K, Hernes E, Kvassheim M, Revheim ME, Bastiansen J, Selboe S, et al. First-in-human phase 0 study of AB001, a prostate-specific membrane antigen-targeted (212)Pb radioligand, in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2025;66:732\u20138. https:\/\/doi.org\/10.2967\/jnumed.124.269299.","journal-title":"J Nucl Med"},{"key":"7754_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12194-023-00702-9","volume":"16","author":"A Takahashi","year":"2023","unstructured":"Takahashi A, Kajiya R, Baba S, Sasaki M. Monte Carlo simulation study to explore optimum conditions for Astatine-211 SPECT. Radiol Phys Technol. 2023;16:102\u20138. https:\/\/doi.org\/10.1007\/s12194-023-00702-9.","journal-title":"Radiol Phys Technol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07754-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07754-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07754-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:08:46Z","timestamp":1779422926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07754-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7754"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07754-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved and performed following the guidelines of the Duke University Institutional Animal Care and Use Committee (IACUC). Human investigation was approved by the West China Hospital Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors have consent to publish all the data in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Michael Zalutsky is a shareholder in Z-Alpha Therapeutics. and is entitled to royalty distributions from Z-Alpha related to the [\n                      211\n                      At]YF2 agent described herein. No other potential conflicts of interest relevant to this article exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}